HLS Therapeutics (TSX:HLS) FCF Margin % : 6.22% (As of Mar. 2024)

View and export this data going back to 1959. Start your Free Trial

What is HLS Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. HLS Therapeutics's Free Cash Flow for the three months ended in Mar. 2024 was C$1.05 Mil. HLS Therapeutics's Revenue for the three months ended in Mar. 2024 was C$16.88 Mil. Therefore, HLS Therapeutics's FCF Margin % for the quarter that ended in Mar. 2024 was 6.22%.

As of today, HLS Therapeutics's current FCF Yield % is 17.01%.

The historical rank and industry rank for HLS Therapeutics's FCF Margin % or its related term are showing as below:

TSX:HLS' s FCF Margin % Range Over the Past 10 Years
Min: -62.97 Med: 24.59 Max: 52.05
Current: 20.65

During the past 13 years, the highest FCF Margin % of HLS Therapeutics was 52.05%. The lowest was -62.97%. And the median was 24.59%.

TSX:HLS's FCF Margin % is ranked better than
94.16% of 1027 companies
in the Drug Manufacturers industry
Industry Median: -0.42 vs TSX:HLS: 20.65

HLS Therapeutics FCF Margin % Historical Data

The historical data trend for HLS Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HLS Therapeutics FCF Margin % Chart

HLS Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

20.40

-62.97

19.86

11.05

24.73

HLS Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial															27.24	16.25	33.47	23.54	6.22

Competitive Comparison of HLS Therapeutics's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, HLS Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HLS Therapeutics's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, HLS Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where HLS Therapeutics's FCF Margin % falls into.

HLS Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

HLS Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	20.929	/	84.62
	=	24.73 %

HLS Therapeutics's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	1.05	/	16.883
	=	6.22 %

HLS Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of HLS Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

HLS Therapeutics (TSX:HLS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HLS Therapeutics Inc (TSX:HLS) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

HLTRF:USA

Address

10 Carlson Court, Suite 701, Etobicoke, ON, CAN, M9W6L2

Website

https://www.hlstherapeutics.com

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company products include Clozaril, Vascepa, Trinomia, and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States, and the Rest of the world.

HLS Therapeutics (TSX:HLS) Headlines

No Headlines